<DOC>
	<DOCNO>NCT00630097</DOCNO>
	<brief_summary>Patients treat methamphetamine dependence high rate relapse , pharmacotherapy yet demonstrate efficacious . Modafinil ( , l-2- [ ( diphenylmethyl ) sulfinyl ] acetamide ) novel wake- vigilance-promoting agent chemically pharmacologically dissimilar CNS stimulant . It well tolerate low abuse liability compare CNS stimulant . Modafinil FDA approve variety sleep disorder , may relieve methamphetamine withdrawal symptom , improve cognitive function , show reduce cocaine use dependent user , safe coadministered intravenous methamphetamine . We conduct randomize dose range clinical trial modafinil establish safety efficacy pharmacotherapy methamphetamine dependence .</brief_summary>
	<brief_title>A Dose Ranging Study Modafinil Methamphetamine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>1 . Age 18 50 year 2 . Patient agreeable condition study sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>methamphetamine addiction , meth dependence</keyword>
</DOC>